Contact
searchSearch
HMP Global
Login

Tumor Treating Fields Specialty Channel

Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Vincent Picozzi, MD
Conference Coverage
TTFields Provide Overall Survival Benefit in Locally Advanced Pancreatic Adenocarcinoma
05/31/2025
Vincent Picozzi, MD
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses...
05/31/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
Allison Casey
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer
07/17/2023
Ticiana Leal, MD
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Conference Coverage
Tumor Treating Fields Combined With Radiotherapy is Well Tolerated in Newly Diagnosed Glioblastoma
06/15/2023
Stephanie Holland
The addition of tumor treating fields to radiotherapy is well tolerated in adult patients with newly diagnosed glioblastoma, according to findings from the phase 1/2 PriCoTTF study.
The addition of tumor treating fields to radiotherapy is well tolerated in adult patients with newly diagnosed glioblastoma, according to findings from the phase 1/2 PriCoTTF study.
The addition of tumor treating...
06/15/2023
Oncology
Matthew Ballo, MD, West Cancer Center
Videos
Tumor Treating Fields Associated With Significant Survival Benefit in Newly Diagnosed Glioblastoma
06/05/2023
Matthew Ballo, MD, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.
Matthew Ballo, MD, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.
Matthew Ballo, MD, discusses...
06/05/2023
Oncology
News
Tumor Treating Fields Improve Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer
01/09/2023
Derek Cowsert
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the...
01/09/2023
Oncology

News

Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Vincent Picozzi, MD
Conference Coverage
TTFields Provide Overall Survival Benefit in Locally Advanced Pancreatic Adenocarcinoma
05/31/2025
Vincent Picozzi, MD
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses...
05/31/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
Allison Casey
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer
07/17/2023
Ticiana Leal, MD
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Conference Coverage
Tumor Treating Fields Combined With Radiotherapy is Well Tolerated in Newly Diagnosed Glioblastoma
06/15/2023
Stephanie Holland
The addition of tumor treating fields to radiotherapy is well tolerated in adult patients with newly diagnosed glioblastoma, according to findings from the phase 1/2 PriCoTTF study.
The addition of tumor treating fields to radiotherapy is well tolerated in adult patients with newly diagnosed glioblastoma, according to findings from the phase 1/2 PriCoTTF study.
The addition of tumor treating...
06/15/2023
Oncology
Matthew Ballo, MD, West Cancer Center
Videos
Tumor Treating Fields Associated With Significant Survival Benefit in Newly Diagnosed Glioblastoma
06/05/2023
Matthew Ballo, MD, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.
Matthew Ballo, MD, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.
Matthew Ballo, MD, discusses...
06/05/2023
Oncology
News
Tumor Treating Fields Improve Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer
01/09/2023
Derek Cowsert
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the...
01/09/2023
Oncology

Interactive Features

Recent News

Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
Allison Casey
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
News
Tumor Treating Fields Improve Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer
01/09/2023
Derek Cowsert
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the...
01/09/2023
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use